Skip to main content
SpringerLink
Log in

Criteria for Diagnosis and Response

  • Chapter
  • First Online:
Book cover Multiple Myeloma

  • 2568 Accesses

Abstract

Multiple myeloma accounts for about 1 % of all types of malignancy and slightly more than 10 % of hematologic malignancies [1]. The incidence of multiple myeloma in the United States has increased from 0.8/100,000 persons in 1949 to 1.7/100,000 in 1963 and then to 3.5/100,000 for males in 1988. The incidence was 3.1/100,000 from 1945 to 1964 in Olmsted County, Minnesota, 2.7/100,000 from 1965 to 1977, 4.1/100,000 from 1978 to 1990, and 4.3/100,000 from 1991 to 2001 [2]. There was no change in incidence in Olmsted County over the 56-year period. The increased incidence reported during the past few decades in The United States is most likely due to the increased availability of medical facilities for elderly patients and improved diagnostic techniques rather than an actual increased incidence. The incidence of multiple myeloma is approximately twice as high in the African-American population as in the white population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR; Mayo Clinic Myeloma, Amyloid; Dysproteinemia Group. Current therapy for multiple myeloma.[see comment]. [Review] [89 refs]. Mayo Clin Proc. 2002; 77(8):813–22.

    Google Scholar 

  2. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ. Incidence of multiple myeloma in Olmsted County, Minnesota—trend over 6 decades. Cancer. 2004;101(11):2667–74.

    Article  PubMed  Google Scholar 

  3. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. [see comment]. Mayo Clin Proc. 2003; 78(1):21–33.

    Article  PubMed  Google Scholar 

  4. Blade J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. [Review] [70 refs]. Leuk Lymphoma. 1998;30(5–6): 493–501.

    PubMed  CAS  Google Scholar 

  5. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis. 1992;20(1):34–41.

    PubMed  CAS  Google Scholar 

  6. Annesley TM, Burritt MF, Kyle RA. Artifactual hypercalcemia in multiple myeloma. Mayo Clin Proc. 1982;57(9):572–5.

    PubMed  CAS  Google Scholar 

  7. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–506.

    Article  PubMed  CAS  Google Scholar 

  8. Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002;117(1):103–8.

    Article  PubMed  Google Scholar 

  9. Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127(3):280–4. Prepublished on 2004/10/20 as doi:10.1111/j.1365-2141.2004.05199.x.

    Google Scholar 

  10. Gozzetti A, Cerase A, Lotti F, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012;118(6):1574–84. Prepublished on 2011/09/21 as doi:10.1002/cncr.26447.

    Google Scholar 

  11. Talamo G, Cavallo F, Zangari M, et al. Hyperammonemia and encephalopathy in patients with multiple myeloma. Am J Hematol. 2007;82(5): 414–5. Prepublished on 2006/11/30 as doi:10.1002/ajh.20808.

    Google Scholar 

  12. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974; 133(5):813–8.

    Article  PubMed  CAS  Google Scholar 

  13. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(5):1044–52.

    Article  PubMed  CAS  Google Scholar 

  14. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9):2900–2. Prepublished on 2001/04/21.

    Google Scholar 

  15. Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood. 2009;114(1): 38–9. Prepublished on 2009/05/05 as doi:10.1182/blood-2009-02-205807.

  16. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem. 2005;51(5):878–81.

    Article  PubMed  CAS  Google Scholar 

  17. Larson D, Kyle RA, Rajkumar SV. Prevalence and monitoring of oligosecretory myeloma. N Engl J Med. 2012;367(6):580–1. Prepublished on 2012/08/10 as doi:10.1056/NEJMc1206740.

    Google Scholar 

  18. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology—an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91(7):2501–7.

    PubMed  CAS  Google Scholar 

  19. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210–21. Prepublished on 2009/10/03 as doi:10.1038/leu.2009.174.

    Google Scholar 

  20. Lacy MQ, Gertz MA, Hanson CA, Inwards DJ, Kyle RA. Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol. 1997;56(4):288–93.

    Article  PubMed  CAS  Google Scholar 

  21. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25(9): 1121–8.

    Article  PubMed  Google Scholar 

  22. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol. 2005;184(4):1199–204. Prepublished on 2005/03/25.

    Google Scholar 

  23. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18): 4701–5. Prepublished on 2011/02/05 as doi:10.1182/blood-2010-10-299529.

  24. Kyle RA. Sequence of testing for monoclonal gammopathies. Arch Pathol Lab Med. 1999;123(2): 114–8.

    PubMed  CAS  Google Scholar 

  25. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20.

    Article  PubMed  Google Scholar 

  26. Snozek CL, Saenger AK, Greipp PR, et al. Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myeloma. Clin Chem. 2007;53(6):1099–103.

    Article  PubMed  CAS  Google Scholar 

  27. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437–44.

    PubMed  CAS  Google Scholar 

  28. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–24.

    Article  PubMed  CAS  Google Scholar 

  29. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood. 2006;108(6):1979–83.

    Article  PubMed  CAS  Google Scholar 

  30. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111(2):785–9.

    Article  PubMed  CAS  Google Scholar 

  31. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812–7.

    Article  PubMed  CAS  Google Scholar 

  32. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860–73.

    Article  PubMed  CAS  Google Scholar 

  33. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001;68(4):269–75.

    Article  PubMed  CAS  Google Scholar 

  34. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol. 2007;20(4):625–35. Prepublished on 2007/12/12 as doi:10.1016/j.beha.2007.08.005.

  35. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115(12):931–5. Prepublished on 1991/12/15.

    Google Scholar 

  36. Moulopoulos LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. Radiology. 1994;193(2):441–6. Prepublished on 1994/11/01.

    Google Scholar 

  37. Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol. 1993;11(7):1311–5. Prepublished on 1993/07/01.

    Google Scholar 

  38. Moulopoulos LA, Dimopoulos MA, Smith TL, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 1995;13(1):251–6.

    PubMed  CAS  Google Scholar 

  39. Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol. 1999;104(4):723–9.

    Article  PubMed  CAS  Google Scholar 

  40. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.

    Article  Google Scholar 

  41. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9.

    Article  PubMed  CAS  Google Scholar 

  42. Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011;365(5):474–5. Prepublished on 2011/08/05 as doi:10.1056/NEJMc1106428.

    Google Scholar 

  43. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton III LJ. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. [see comment]. Mayo Clin Proc. 2004;79(7):859–66.

    Article  PubMed  Google Scholar 

  44. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. [see comment]. N Engl J Med. 2002;346(8):564–9.

    Article  PubMed  Google Scholar 

  45. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302(24):1347–9.

    Article  PubMed  CAS  Google Scholar 

  46. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25): 2582–90.

    Article  PubMed  CAS  Google Scholar 

  47. Maldonado JE, Kyle RA, Brown Jr AL, Bayrd ED. “Intermediate” cell types and mixed cell proliferation in multiple myeloma: electron microscopic observations. Blood. 1966;27(2):212–26.

    PubMed  CAS  Google Scholar 

  48. Kyle RA, Bayrd ED. “Primary” systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases. Arch Intern Med. 1961;107:344–53. Prepublished on 1961/03/01.

    Google Scholar 

  49. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115–23.

    Article  PubMed  CAS  Google Scholar 

  50. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by National Cancer Institute grants CA168762, CA 107476, CA 100707, CA90297052, and CA 83724. Also supported in part by ECOG CA 21115T, the Jabbs Foundation (Birmingham, United Kingdom), and the Henry J. Predolin Foundation, USA.

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA

    Robert A. Kyle M.D.

  2. Division of Hematology, Myeloma Amyloidosis Dysproteinemia Group, Mayo Clinic, Rochester, MN, USA

    S. Vincent Rajkumar M.D.

Authors
  1. Robert A. Kyle M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Vincent Rajkumar M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert A. Kyle M.D. .

Editor information

Editors and Affiliations

  1. Mayo Clinic, Department of Internal Medicine Division of Hematology, Rochester, Minnesota, USA

    Morie A. Gertz

  2. Mayo Clinic, Myeloma Amyloidosis Dysproteinemia Group Division of Hematology, Rochester, Minnesota, USA

    S. Vincent Rajkumar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Mayo Foundation for Medical Education and Research

About this chapter

Cite this chapter

Kyle, R.A., Rajkumar, S.V. (2014). Criteria for Diagnosis and Response. In: Gertz, M., Rajkumar, S. (eds) Multiple Myeloma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8520-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8520-9_1

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8519-3

  • Online ISBN: 978-1-4614-8520-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation